August 3, 2012 – A federal judge has denied a motion filed by pharmaceutical giant Boehringer Ingelheim to throw a number of Pradaxa lawsuits out of court, ruling that prior warnings about internal bleeding were insufficient to have the cases dismissed.
Free Pradaxa Lawsuit Evaluation: If you or a loved one has been injured by Pradaxa, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.
What’s the problem?
In addition to Judge David R. Herndon’s refusal to dismiss the Pradaxa lawsuits, the U.S. Judicial Panel on Multidistrict Litigation (JPML) is currently in the process of determining whether all similar cases filed in the federal court system will be consolidated for pretrial handling.
At least 17 of the federal Pradaxa internal bleeding lawsuits are currently centralized before Herndon in the Southern District of Illinois, represent approximately half of the total number of such claims filed in the federal court system.
First approved by the U.S. Food & Drug Administration (FDA) in October 2010, Pradaxa (generic: dabigatran) is a widely-prescribed anticoagulant medication used for the prevention of strokes in patients with atrial fibrillation. Boehringer originally marketed the drug as superior to Coumadin (generic: warfarin) because it supposedly requires less patient monitoring to treat. However, if an internal bleeding event occurs in a patient being treated with Coumadin, it can be quickly counteracted with a single dose of vitamin K, whereas with Pradaxa there is no such antidote.
In response to a number of complaints filed shortly after Pradaxa first hit the market, Boehringer filed a Motion to Dismiss pursuant to Federal Rule 12(b)(g), alleging that the suits failed to state a valid claim upon which they could be successful. The company argued that Pradaxa warning labels contained information about internal bleeding events from Pradaxa, therefore the lawsuits should be thrown out of court.
Judge Herndon disagreed with the motion, pointing out that the failure to warn lawsuits also allege that Boehringer failed to adequately inform the public and medical communities about the lack of antidote with Pradaxa, and that the drug had been linked to reports of excessive and uncontrollable bleeding. Therefore, Herndon ruled that “including a warning about the risk of serious or fatal bleeding does not justify dismissal of plaintiff’s claims.”
Do I Have a Pradaxa Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Pradaxa lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.
Free Confidential Case Evaluation: Again, if you or a loved one was injured by Pradaxa, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.